Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Morning Intake of Simvast Controlled Release (CR) Tablet Versus Evening Intake of Zocor Tablet in Chronic Kidney Disease Stage(CKD)3, 4 and 5 Patients With Hyperlipidemia: A Randomized, Double-blind, Multicenter Phase 4 Trial (HM-SIM4)

NCT01564875 is registered in ClinicalTrials.gov with Hanmi Pharmaceutical Company Limited as lead sponsor.

NCT NCT01564875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01564875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Morning Intake of Simvast Controlled Release (CR) Tablet Versus Evening Intake of Zocor Tablet in Chronic Kidney Disease Stage(CKD)3, 4 and 5 Patients With Hyperlipidemia: A Randomized, Double-blind, Multicenter Phase 4 Trial (HM-SIM4)
Lead sponsor
Hanmi Pharmaceutical Company Limited
Phase
Phase 4
Overall status
Unknown status
Start date
December 31, 2010
Completion date
May 31, 2012
Enrollment
122 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, hyperlipidemia